BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, announced today that it has
completed the dose escalation stage of a Phase 1 trial for its novel
oncology platform, BL-8040, as a novel treatment for the mobilization of
stem cells from the bone marrow to the peripheral blood circulation. All
healthy volunteers completed the treatment phase and results are
expected during the first quarter of 2015. BL-8040 is being developed
along multiple tracks for the treatment of hematological malignancies
and other hematological indications, with multiple clinical milestones
expected in 2015.
Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx, stated, “We
are very excited about this latest advancement for our BL-8040 platform.
Stem cell mobilization is used increasingly as a method of collecting
hematopoietic stem cells for transplantation, forming part of the
treatment regimen for certain types of hematological cancers, as well as
severe anemia or immune deficiency disorders. Although it is a Phase 1
study, the current trial will provide us with efficacy data regarding
the mobilization capacity of one or two injections of BL-8040 as a
stand-alone therapy, which could significantly shorten and reduce the
cost of treatment, as well as eliminate the painful side effects
associated with G-CSF.”
“In parallel, BL-8040 is also undergoing a Phase 2 study for treating
relapsed and refractory acute myeloid leukemia patients, the results of
which are expected in the second half 2015. The robust mobilization of
cells seen in our Phase 2 AML study to date has been very encouraging
and will hopefully be reflected in our Phase 1 mobilization study.”
“As recently reported, we also expect to commence clinical trials for
three additional indications for BL-8040 during 2015,” concluded Dr.
Savitsky.
The Phase 1 study consists of two parts. The first part is a randomized,
double-blind, placebo-controlled dose escalation study exploring the
safety and tolerability of escalating repeated doses of BL-8040 in
healthy volunteers. Secondary objectives include assessment of the
efficacy of BL-8040 in mobilizing stem cells as a stand-alone therapy,
as well as determining the pharmacodynamic and pharmacokinetic profile
of the drug. This part was performed in three cohorts, with eight
healthy volunteers in each cohort. Following analysis of the data, the
optimal safe and efficacious dose of BL-8040 will be selected to be used
as a stand-alone therapy in the second part of the study.
The second part of the study is an open-label study designed to assess
BL-8040’s stem cell mobilization capacity, as well as the yield of cells
collected by apheresis. Secondary endpoints of the study include
evaluation of the viability and biological activity of cells mobilized
by BL-8040 and collected by apheresis. This part will be performed in a
single cohort of eight healthy volunteers who will receive the selected
dose regimen of BL-8040 based on the data from the first part of the
study.
About Stem Cell Mobilization
High-dose chemotherapy followed by stem cell transplantation has become
an established treatment modality for a variety of hematologic
malignancies, including multiple myeloma, as well as various forms of
lymphoma and leukemia. Modern peripheral stem-cell harvesting often
replaces the use of traditional surgical bone marrow stem-cell
harvesting. In the modern method, stem cells are mobilized from the bone
marrow using granulocyte colony-stimulating factor (G-CSF), often with
the addition of a mobilizing agent such as Plerixafor (Mozobil),
harvested from the donor’s peripheral blood by apheresis, and infused to
the patient after chemotherapy ablation treatment. This treatment is
highly effective, the peripheral stem cells are easier to collect, and
the treatment allows for a quicker recovery time and fewer complications.
About BL-8040
BL-8040 is a clinical-stage drug candidate for the treatment of acute
myeloid leukemia, as well as other hematological indications. It is a
short peptide that functions as a high-affinity antagonist for CXCR4, a
chemokine receptor that is directly involved in tumor progression,
angiogenesis (growth of new blood vessels in the tumor), metastasis
(spread of the disease to other organs or organ parts) and cell
survival. CXCR4 is over-expressed in more than 70% of human cancers and
its expression often correlates with disease severity. In a Phase 1/2,
open-label, dose escalation, safety and efficacy clinical trial in 18
multiple myeloma patients, BL-8040 demonstrated an excellent safety
profile at all doses tested and was highly effective in the mobilization
of hematopoietic stem cells and white blood cells from the bone marrow
to the peripheral blood.
BL-8040 also mobilizes cancer cells from the bone marrow and may
therefore sensitize these cells to chemo- and bio-based anti-cancer
therapy. Importantly, BL-8040 has also demonstrated a direct anti-cancer
effect by inducing apoptosis. Pre-clinical studies show that BL-8040 is
efficient, both alone and in combination with the anti-cancer drug
Rituximab, in reducing bone marrow metastasis of lymphoma cells and
stimulating lymphoma cell death. In addition, the current Phase 2
clinical trial in AML patients has demonstrated robust mobilization and
apoptosis of cancer cells. BL-8040 was licensed by BioLineRx from
Biokine Therapeutics and was previously developed under the name BKT-140.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based
in Israel, develops them through pre-clinical and/or clinical stages,
and then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a
pivotal CE-Mark registration trial scheduled for completion in mid-2015;
BL-8040, a cancer therapy platform, which is in the midst of a Phase 2
study for acute myeloid leukemia (AML) as well as a Phase 1 study for
stem cell mobilization; and BL-7010 for celiac disease, which has
successfully completed a Phase 1/2 study.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as
the Google Play Store.
Various statements in this release concerning BioLineRx’s future
expectations, including specifically those related to the development
and commercialization of BL-8040, constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements include words such as “may,”
“expects,” “anticipates,” “believes,” and “intends,” and describe
opinions about future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially
different from any future results, performance or achievements expressed
or implied by such forward-looking statements. Some of these risks are:
changes in relationships with collaborators; the impact of competitive
products and technological changes; risks relating to the development of
new products; and the ability to implement technological improvements.
These and other factors are more fully discussed in the “Risk Factors”
section of BioLineRx’s most recent annual report on Form 20-F filed with
the Securities and Exchange Commission on March 17, 2014. In addition,
any forward-looking statements represent BioLineRx’s views only as of
the date of this release and should not be relied upon as representing
its views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required by
law.
Copyright Business Wire 2015